LeMaitre Vascular is a medical instruments & supplies business based in the US. LeMaitre Vascular shares (LMAT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $101.52 – a decrease of 2.62% over the previous week. LeMaitre Vascular employs 614 staff and has a trailing 12-month revenue of around $213 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $101.52 |
|---|---|
| 52-week range | $51.37 - $106.49 |
| 50-day moving average | $91.83 |
| 200-day moving average | $79.10 |
| Wall St. target price | $98.78 |
| PE ratio | 56.4 |
| Dividend yield | $0.62 (0.62%) |
| Earnings per share (TTM) | $1.80 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $101.52 from 2024-11-14
| 1 week (2024-11-08) | -2.62% |
|---|---|
| 1 month (2024-10-16) | 10.93% |
| 3 months (2024-08-16) | 19.79% |
| 6 months (2024-05-16) | 30.69% |
| 1 year (2023-11-16) | 91.62% |
|---|---|
| 2 years (2022-11-16) | 126.86% |
| 3 years (2021-11-16) | 95.76% |
| 5 years (2019-11-15) | 210.75% |
Valuing LeMaitre Vascular stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LeMaitre Vascular's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
LeMaitre Vascular's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 56x. In other words, LeMaitre Vascular shares trade at around 56x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
LeMaitre Vascular's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2519. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into LeMaitre Vascular's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
LeMaitre Vascular's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $59.2 million.
The EBITDA is a measure of a LeMaitre Vascular's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $213 million |
|---|---|
| Operating margin TTM | 23.98% |
| Gross profit TTM | $104.9 million |
| Return on assets TTM | 8.72% |
| Return on equity TTM | 13.34% |
| Profit margin | 19.4% |
| Book value | $14.73 |
| Market Capitalization | $2.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 34.97% of net profits
Recently LeMaitre Vascular has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), LeMaitre Vascular shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In LeMaitre Vascular's case, that would currently equate to about $0.62 per share.
While LeMaitre Vascular's payout ratio might seem fairly standard, it's worth remembering that LeMaitre Vascular may be investing much of the rest of its net profits in future growth.
LeMaitre Vascular's most recent dividend payout was on 4 December 2024. The latest dividend was paid out to all shareholders who bought their shares by 20 November 2024 (the "ex-dividend date").
Over the last 12 months, LeMaitre Vascular's shares have ranged in value from as little as $51.3662 up to $106.489. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LeMaitre Vascular's is 0.885. This would suggest that LeMaitre Vascular's shares are less volatile than average (for this exchange).
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.